Explore chapters and articles related to this topic
Monographs of Topical Drugs that Have Caused Contact Allergy/Allergic Contact Dermatitis
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
In a report on contact allergy to nystatin, the patient had a negative reaction to fluocinolone, present in the combination product containing nystatin. However, the authors stated that they had observed a case of contact allergy to fluocinolone acetonide a few years previously. Clinical and patch testing details were not provided (3).
Fluocinolone acetonide sustained drug-delivery implant for posterior segment eye diseases
Published in A Peyman MD Gholam, A Meffert MD Stephen, D Conway MD FACS Mandi, Chiasson Trisha, Vitreoretinal Surgical Techniques, 2019
Ideally, a corticosteroid delivery device should provide therapeutic drug levels over the duration of the patient’s disease. Fluocinolone acetonide is a synthetic corticosteroid with low solubility in aqueous solution. The solubility of fluocinolone acetonide is that of dexamethasone, which itself is relatively insoluble. Theoretically, this low solubility should allow very extended drug release from a delivery device without the need for an excessively bulky polymer system. A study was undertaken to determine the feasibility of constructing a fluocinolone acetonide device, to test the hypothesis that this device would provide sustained drug delivery in vitro and in vivo, and to evaluate the safety of this device in the rabbit eye.
Autoimmune endocrine disease
Published in Philip E. Harris, Pierre-Marc G. Bouloux, Endocrinology in Clinical Practice, 2014
Terry J. Smith, Laszlo Hegedüs
Treatment of dermopathy usually results in disappointing responses. Corticosteroids have been administered either systemically, by intralesional injection, or through topical application. The side effects of these agents and the frequently mild clinical course taken by dermopathy make the use of steroids unattractive in the majority of cases. Some experts advocate the use of topical agents such as fluocinolone acetonide applied under occlusive film. This can be repeated several times each week until the process seems to abate. The frequency of application can then be reduced to a few times each month. Elastic stockings are said to slow the rate of lesion recurrence. Surgical remediation in the form of skin grafts and excisional biopsies are usually futile because the disease can return.
Indicators of Post-Operative Intraocular Pressure Elevation after Naïve Fluocinolone Acetonide Surgical Implantation
Published in Ocular Immunology and Inflammation, 2020
Aaron J. Sadowsky, Paula E. Pecen, Eric Feinstein, Alan G. Palestine
Posterior uveitis often requires treatment with intravitreal or periocular corticosteroids or systemic immunosuppression as it is usually not responsive to topical medications prescribed for anterior uveitis.7 Corticosteroid therapies for noninfectious uveitis resulting in elevated IOP have been well-described; one-third of eyes treated with topical corticosteroid therapy such as betamethasone or dexamethasone for noninfectious uveitis develop elevated IOP.4,8–10 Other forms of local corticosteroid therapy have been found to elevate IOP as well. For example, 34.6% of patients receiving intravitreal triamcinolone acetonide therapy for a variety of posterior segment disorders experienced IOP elevation in excess of 21 mmHg from baseline, within 12 months post-injection.11 Additionally, data from the POINT study showed that both an intravitreal triamcinolone acetonide implant, as well as an intravitreal dexamethasone implant, were superior modes of treatment for treating uveitic macular edema in comparison to periocular triamcinolone acetonide.12 Fluocinolone acetonide (FA) intravitreal surgical implantation (Retisert; Bausch & Lomb, Inc., Rochester, New York, USA) is preferable in some patients to avoid repeated injections and provide long-term stable inflammation control, whereas the three drugs studied in the POINT study had a maximum effect at 12 weeks, but no direct comparison with FA implants was done.12
Development of Nanofibrous Ocular Insert for Retinal Delivery of Fluocinolone Acetonide
Published in Current Eye Research, 2019
Jatin Singla, Tanya Bajaj, Amit K Goyal, Goutam Rath
Fluocinolone acetonide at a working dose on assisting formulation minimizes tissue damage when compared with plain drug. Histopathological analysis showed that the retinal pigment epithelium (RPE) which helps in the nourishment of retinal visual cells was found to be of 28.4 µm. Figure 7 represents the density of cons 400 to 500/µm2 and the density of rods was found to be 100 to 200/µm2, considering optimum for the colour vision for the eye. This shows that the drug has no effect on retina.15 However, relatively higher toxicity was observed in marketed formulation characterized by typical tissue structure, which could be attributed with pharmacokinetic profile with multifold higher Cmax compared to prepared formulation. However, these variations can be neglected. No inflammatory cells were found in the histological sections of the retina, indicating that the prepared formulation has no sign of ocular toxicity at the target site.
Development and characterization of pluronic lecithin organogel containing fluocinolone acetonide
Published in Drug Development and Industrial Pharmacy, 2021
Fluocinolone acetonide (FA) is one of the glucocorticoids applied for the prevention of inflammatory skin conditions. It is a BCS class II drug and hence to achieve the controlled release of drugs through topical drug delivery systems was done by different novel drug delivery systems such as liposomes, microsponge, nanostructured lipid carrier in the literature [4–6]. But as the general limitations of the nanoparticulate system such as low % drug loading, stability issues as well as the difficulty in scale-up due to novel technology and higher costing, there is a need to develop the formulation which can control the release of FA to decrease the systemic absorption as well as to reduce the dosing frequency.